Payment overview · 2025
General Payments
$180.73
6 reported records · 5 companies
Healthcare provider profile · identity verified
Micah Boyer, MD
Allopathic & Osteopathic Physicians|Family Medicine · WICHITA FALLS, TX · NPI 1306289087
Verified facts
What the public records show
CMS Open Payments records show Micah Boyer, MD received $180.73 in general payments during 2025 across 6 reported records.
MERZ NORTH AMERICA, INC. accounted for 54.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Rybelsus by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Tresiba as an associated drug or biological on 415 records involving 264 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Tresiba by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| MERZ NORTH AMERICA, INC. | Unresolved — no canonical attribution shown | $98.76 | 54.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $30.00 | 16.6% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.00 | 10.0% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $17.68 | 9.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.29 | 9.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $180.73 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Xeomin Normalized: xeomin |
Biological | MERZ NORTH AMERICA, INC. | $98.76 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $18.00 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $17.68 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.44 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.29 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $13.56 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $13.56 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 84 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 43 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 89 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
89 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
84 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
43 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Tresiba open payments reported associated product |
CMS Open Payments — General Payments 415 supporting records · 264 recipient NPIs · example record 1188130328 |
Tresiba · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 989 | 171 |
| Atorvastatin Calcium | Atorvastatin Calcium | 421 | 126 |
| Gabapentin | Gabapentin | 381 | 97 |
| Levothyroxine Sodium | Levothyroxine Sodium | 362 | 93 |
| Eliquis | Apixaban | 341 | 50 |
| Meloxicam | Meloxicam | 315 | 99 |
| Tramadol Hcl | Tramadol Hcl | 289 | 67 |
| Furosemide | Furosemide | 282 | 85 |
| Amlodipine Besylate | Amlodipine Besylate | 273 | 83 |
| Omeprazole | Omeprazole | 273 | 75 |
| Trazodone Hcl | Trazodone Hcl | 240 | 76 |
| Methadone Hcl | Methadone Hcl | 224 | 34 |
| Buspirone Hcl | Buspirone Hcl | 210 | 54 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 209 | 21 |
| Potassium Chloride | Potassium Chloride | 203 | 52 |
| Pregabalin | Pregabalin | 188 | 59 |
| Morphine Sulfate Er | Morphine Sulfate | 186 | 32 |
| Tizanidine Hcl | Tizanidine Hcl | 180 | 44 |
| Lisinopril | Lisinopril | 178 | 64 |
| Losartan Potassium | Losartan Potassium | 177 | 59 |
| Alprazolam | Alprazolam | 175 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 168 | 63 |
| Montelukast Sodium | Montelukast Sodium | 167 | 50 |
| Escitalopram Oxalate | Escitalopram Oxalate | 161 | 40 |
| Budesonide | Budesonide | 160 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 155 | 57 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 150 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 148 | 48 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 147 | 40 |
| Famotidine | Famotidine | 146 | 39 |
| Carvedilol | Carvedilol | 137 | 39 |
| Donepezil Hcl | Donepezil Hcl | 134 | 32 |
| Metformin Hcl | Metformin Hcl | 133 | 39 |
| Sertraline Hcl | Sertraline Hcl | 132 | 26 |
| Metoprolol Succinate | Metoprolol Succinate | 125 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 123 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 122 | 40 |
| Fentanyl | Fentanyl | 113 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 108 | 33 |
| Methocarbamol | Methocarbamol | 107 | 40 |
| Bydureon Bcise | Exenatide Microspheres | 104 | 19 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 90 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 89 | 23 |
| Bupropion Xl | Bupropion Hcl | 87 | 27 |
| Ozempic | Semaglutide | 84 | 17 |
| Morphine Sulfate | Morphine Sulfate | 83 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 81 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 78 | 23 |
| Prednisone | Prednisone | 76 | 52 |
| Spironolactone | Spironolactone | 76 | 26 |
| Baclofen | Baclofen | 74 | 25 |
| Ondansetron Hcl | Ondansetron Hcl | 74 | 37 |
| Allopurinol | Allopurinol | 71 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 70 | 41 |
| Movantik | Naloxegol Oxalate | 70 | 12 |
| Glipizide Er | Glipizide | 69 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 65 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 61 | 17 |
| Ibuprofen | Ibuprofen | 57 | 24 |
| Trulicity | Dulaglutide | 57 | 17 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 55 | suppressed |
| Finasteride | Finasteride | 55 | 18 |
| Azithromycin | Azithromycin | 54 | 41 |
| Dicyclomine Hcl | Dicyclomine Hcl | 53 | 23 |
| Lorazepam | Lorazepam | 52 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 52 | suppressed |
| Topiramate | Topiramate | 52 | 15 |
| Linzess | Linaclotide | 50 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 50 | suppressed |
| Mirtazapine | Mirtazapine | 49 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 48 | 13 |
| Divalproex Sodium | Divalproex Sodium | 48 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 48 | 17 |
| Jardiance | Empagliflozin | 47 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 47 | 13 |
| Metformin Hcl Er | Metformin Hcl | 46 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 46 | 12 |
| Rybelsus | Semaglutide | 43 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | 12 |
| Estradiol | Estradiol | 40 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 40 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | 11 |
| Levetiracetam | Levetiracetam | 39 | suppressed |
| Ondansetron Odt | Ondansetron | 37 | 21 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 37 | 30 |
| Amiodarone Hcl | Amiodarone Hcl | 36 | suppressed |
| Sucralfate | Sucralfate | 36 | 14 |
| Bumetanide | Bumetanide | 34 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 27 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 34 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 34 | suppressed |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Primidone | Primidone | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 17 |
| Chlorthalidone | Chlorthalidone | 30 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 30 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 30 | 12 |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 29 | 15 |
| Mounjaro | Tirzepatide | 28 | suppressed |
| Temazepam | Temazepam | 28 | suppressed |
| Nystatin | Nystatin | 27 | 15 |
| Risperidone | Risperidone | 27 | suppressed |
| Invokana | Canagliflozin | 26 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Telmisartan | Telmisartan | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 24 | suppressed |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Celecoxib | Celecoxib | 23 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 23 | suppressed |
| Levemir | Insulin Detemir | 23 | suppressed |
| Meropenem | Meropenem | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 19 |
| Insulin Aspart Flexpen | Insulin Aspart | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 20 | suppressed |
| Tradjenta | Linagliptin | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Simvastatin | Simvastatin | 19 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 19 | suppressed |
| Enulose | Lactulose | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 18 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 18 | suppressed |
| Progesterone | Progesterone, Micronized | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 13 |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Scopolamine | Scopolamine | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 14 | suppressed |
| Cimetidine | Cimetidine | 14 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 14 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Tresiba | Insulin Degludec | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Cefepime | Cefepime In Iso-Osm Dextrose | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Np Thyroid | Thyroid,pork | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Insulin Aspart | Insulin Aspart | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Roflumilast | Roflumilast | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $180.73 · 6 records | MERZ NORTH AMERICA, INC. | Kerendia, Ozempic, Rybelsus, TRELEGY ELLIPTA, Wegovy, Xeomin, YUPELRI | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error